Literature DB >> 7039435

Rifampicin-induced early phase hyperglycemia in humans.

N Takasu, T Yamada, H Miura, S Sakamoto, M Korenaga, K Nakajima, M Kanayama.   

Abstract

Early phase hyperglycemia, associated with increased rates of insulin and C-peptide secretion after oral administration of 100 g glucose, was observed among patients with pulmonary tuberculosis who were taking rifampicin. This early phase hyperglycemia appeared shortly after rifampicin was started and it disappeared completely a few days after rifampicin was discontinued. No difference in oral glucose tolerance was noted between healthy normal subjects and patients with pulmonary tuberculosis who were not taking any medications. Antituberculous drugs other than rifampicin did not induce early phase hyperglycemia. Because intravenous glucose tolerance was normal in patients treated with rifampicin, it is suggested that rifampicin produces an early phase hyperglycemia possibly by augmenting intestinal absorption of glucose.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7039435     DOI: 10.1164/arrd.1982.125.1.23

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  25 in total

1.  Serum- and glucocorticoid-regulated kinase 2 determines drug-activated pregnane X receptor to induce gluconeogenesis in human liver cells.

Authors:  Saki Gotoh; Masahiko Negishi
Journal:  J Pharmacol Exp Ther       Date:  2013-11-07       Impact factor: 4.030

Review 2.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

Review 3.  Novel functions of PXR in cardiometabolic disease.

Authors:  Changcheng Zhou
Journal:  Biochim Biophys Acta       Date:  2016-02-26

4.  Degradation of myxovirus virion RNA by periodate.

Authors:  G A Tannock; I P Griffith
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

Review 5.  Drug-induced disorders of glucose metabolism. Mechanisms and management.

Authors:  J C Chan; C S Cockram; J A Critchley
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 6.  Drug-Induced Hyperglycaemia and Diabetes.

Authors:  Neila Fathallah; Raoudha Slim; Sofien Larif; Houssem Hmouda; Chaker Ben Salem
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.606

7.  Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.

Authors:  Lindsey H M Te Brake; Jeroen J M W van den Heuvel; Aaron O Buaben; Reinout van Crevel; Albert Bilos; Frans G Russel; Rob E Aarnoutse; Jan B Koenderink
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 8.  The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.

Authors:  Bryan Mackowiak; Jessica Hodge; Sydney Stern; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2018-05-14       Impact factor: 3.922

Review 9.  Clinical management of concurrent diabetes and tuberculosis and the implications for patient services.

Authors:  Anca Lelia Riza; Fiona Pearson; Cesar Ugarte-Gil; Bachti Alisjahbana; Steven van de Vijver; Nicolae M Panduru; Philip C Hill; Rovina Ruslami; David Moore; Rob Aarnoutse; Julia A Critchley; Reinout van Crevel
Journal:  Lancet Diabetes Endocrinol       Date:  2014-09       Impact factor: 32.069

Review 10.  Avoidance and management of adverse reactions to antituberculosis drugs.

Authors:  A M Patel; J McKeon
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.